Carcinoid disease: Review of the literature

Diseases of the Colon and Rectum

Volumn 40, Issue 3, 1997, Pages 349-362

  Neary, Paul C ^a   Redmond, Paul H ^a   Houghton, Timothy ^a   Watson, Gordon R K ^a   Bouchier Hayes, David ^a  

^a BEAUMONT HOSPITAL   (Ireland)

Author keywords

5 Hydroxyindole acetic acid; Carcinoid; Neuroendocrine tumors; Octreotide

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DACARBAZINE; FLUOROURACIL; RECOMBINANT ALPHA INTERFERON; STREPTOZOCIN;

CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CARCINOGENESIS; CARCINOID; DRUG INDUCED DISEASE; FATIGUE; GASTROINTESTINAL SYMPTOM; HUMAN; MYALGIA; PATHOPHYSIOLOGY; PROGNOSIS; REVIEW; STOMACH TUMOR;

CARCINOID TUMOR; HUMANS; INCIDENCE; PROGNOSIS; RISK FACTORS; TREATMENT OUTCOME;

EID: 0030896695     PISSN: 00123706     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02050428     Document Type: Review

References (182)

1. Lubarsch O. Ueber den primaren Krebs des Ileum, nebst Bemerhunge uber das gleichzeitge Vorkommen von Krebs und Tuberculose. Virchows Arch 1888;111: 280-317.
2. Oberndorfer S. Uber die "kleinen Dunndarm Carcinome." Verb Dtsch Ges Pathol 1907;11:113-6.
3. Ranson WB. Case of primary carcinoma of ileum. Lancet 1890;2:1020.
4. Masson, P. Carcinoids (argentaffin-cell tumors) and nerve hyperplasia of appendicular mucosa. Am J Patholol 1928;4:181-212.
5. Gosset A, Masson P. Tumeurs endocinne de l'appendice. Presse Med 1914;22:237-40.
6. Lembech F. 5-Hydroxytryptamine in carcinoid tumor [letter]. Nature 1953;172:910-1.
7. Page IH, Corcoran AC, Vollenfrend S, et al. Argentaffinoma as an endocrine tumor. Lancet 1955;1:198-9.
8. Woods HF, Bax ND, Anisworth I. Abdominal carcinoid tumors in Sheffield. Digestion 1990;45(Suppl 1):17-22.
9. Newton JN, Swerdlow AJ, dos Santos Silva IM, et al. The epidemiology of carcinoid tumors in England and Scotland. Br J Cancer 1994;70:939-42.
10. Lu Cortez L, Clemente C, Puig V, Mirada A. Tumor carcinoide: analises de 131 casos. Rev Clin Esp 1994; 194:291-3.
11. Moertel CG, Sauer WG, Docherty MB, Baggenstoss AH. Life history of the carcinoid tumor of the small intestine. Cancer 1961;14:901-12.
12. Zeitels J, Naunheim K, Kaplan EL, Straus F. Carcinoid tumors: a 37 year experience. Arch Surg 1982;117: 732-7.
13. Parkes SE, Muir KR, al Sheyyab M, et al. Carcinoid tumors of the appendix in children 1957-1986: incidence, treatment and outcome. Br J Surg 1993;80: 502-4.
14. Eller R, Frazee R, Roberts J. Gastrointestinal carcinoid tumors. Am Surg 1991;57:434-7.
15. Matsui K, Iwase T, Kitagawa M. Small polypoid-appearing carcinoid tumors of the rectum: clinicopathologic study of 16 cases and effectiveness of endoscopic treatment. Am J Gastroenterol 1993;88:1949-53.
16. Williams ED, Sandler M. The classification of carcinoid tumors. Lancet 1963;1:238-9.
17. Zeiger MA, Swartz SE, MacGillivray DC, Linnoila I, Shakir M. Thymic carcinoid in association with MEN syndromes. Am Surg 1992;58:430-4.
18. Burcharth F, Axelsson C. Lung carcinoids. Scand J Thorac Cardiovasc Surg 1973;7:72-7.
19. Goldman NC, Hood CI, Singleton GT. Carcinoid of the larynx. Arch Otolaryngol 1969;90:64-7.
20. Robboy SJ, Norris HJ, Scully RE. Insular carcinoid primary in the ovary: a clinicopathologic analysis of 48 cases. Cancer 1975;36:404-18.
21. Yalla SV, Yalla SS, Morgan JW, Eberhart CA, Olley JE. Primary argentaffinoma of the testis: a case report and survey of the literature. J Urol 1974;111:50-2.
22. Sylora HO, Diamond HM, Kaufman M, Straus F 2nd, Lyons ES. Primary carcinoid tumor of the urethra. J Urol 1975;114:150-3.
23. Hughes JP, Ancalmo N, Leonard GL, Ochsner JL. Carcinoid tumor of the thymus gland: report of a case. Thorax 1975;30:470-5.
24. Porter JM, Kalloo AN, Abernathy EC, Yeo CJ. Carcinoid rumor of the gall bladder: laparoscopic resection and review of the Literature. Surgery 1992;112:100-5.
25. Wilson H, Cheh RC, Sherman RT. et al. Carcinoid tumors. Curr Probl Surg 1970;7:72-7.
26. Gabos S, Berkel J, Band P, Robson D, Whittaker H. Small bowel cancer in western Canada. Int J Epidemiol 1993;22:198-206.
27. Martensson H, Bottcher G, Hambraeus G, Sundler F, Willen H, Nobin A. Bronchial carcinoids: an analysis of 91 cases. World J Surg 1987;11:356-64.
28. Ahlman H, Wangberg B, Nilsson O, et al. Aspects on diagnosis and treatment of the foregut carcinoid syndrome. Scand J Gastroenterol 1992;27:459-71.
29. Jetmore AB, Ray JE, Gathright JB Jr, McMullen KM, Hicks TC, Timmcke AE. Rectal carcinoids: the most frequent carcinoid tumor. Dis Colon Rectum 1992;35: 717-25.
30. Beaton HL. Carcinoid tumors of the alimentary tract. Cancer 1982;32:92-9.
31. Creutzfeldt W. Carcinoid tumors: development of our knowledge. World J Surg 1996;20:126-31.
32. Pentilla IA. Histochemical reactions of the enterochromaffin cells and the 5-hydroxytryptamine content of the mammalian duodenum. Acta Physiol Scand 1966;74(Suppl):218.
33. Soga J, Tazawa K. Pathologic analysis of carcinoids: histologic reevaluation of 62 cases. Cancer 1971;28: 990-8.
34. Kloppel G, Heitz PU, Capella C, Solcia E. Pathology and nomenclature of human gastrointestinal neuroendocrine (carcinoid) tumors and related lesions. World J Surg 1996;20:132-41.
35. Sagara M, Sugiyama F, Horiguchi H, et al. Activation of the nuclear oncogenes N-myc and c-jun in carcinoid tumors of transgenic mice carrying the human genome adenovirus type 12 E1 region gene. DNA Cell Biol 1995;14:95-101.
36. Dietrich WF, Radany EH, Smith JS, Bishop JM, Hanahan D, Lander ES. Genome wide search for loss of heterozygosity in transgenic mouse tumors reveals candidate tumor suppressor genes on chromosomes 9 and 16. Proc Natl Acad Sci U S A 1994;91:9451-5.
37. O'Dowd G, Gosney JR. Absence of over expression of p53 protein by intestinal carcinoid tumors. J Pathol 1995;175:403-4.
38. Lohmann DR, Funk A, Niedermeyer HP, Haupel S, Hofler H. Identification of p53 gene mutations in gastrointestinal and pancreatic carcinoids by nonradioisotopic SSCA. Virchows Arch B 1993;64:293-6.
39. Lohmann DR, Fesseler B, Putz B, et al. Infrequent mutations of the p53 gene in pulmonary carcinoid tumors. Cancer Res 1993;53:5797-801.
40. Kahler HJ, Heilmeyer L. Klinik und patholphysiologie des Karzinoids und Karzinoid syndromes unter besonderer Berucksichtigung der pharmocologie des 5-Hydroxytryptamins. Ergeb Inn Med Kinderheilkd 1961: 16:292.
41. Grahame-Smith DG. The carcinoid syndrome. London: W Heinemann Medical Books, 1972:18-20.
42. Granerus G, Lindell SE, Waldenstrom J, Westling H, White T. Histamine metabolism in carcinoidosis. Lancet 1966;1:1267-8.
43. Grahame-Smith DG. What is the cause of the carcinoid flush? Gut 1987;28:1413-6.
44. Roberts LJ 2nd, Bloomgarden ZT, Marney SR Jr, Rabin D, Oates JA. Histamine release from a gastric carcinoid: provocation by pentagastrin and inhibition by somatostatin. Gastroenterology 1983;84:272-5.
45. Todd TR, Cooper JD, Weissberg D, Delarue NC, Peason FG. Bronchial carcinoid tumors: twenty years experience. J Thoracic Cardiovasc Surg 1980;79:532-6.
46. Norheim I, Theodorsson-Norheim E, Brodin E, Oberg K. Tachykinins in carcinoid tumors; the use as a tumor marker and possible role in the carcinoid flush. J Clin Endocrinol Metab 1986;63:605-12.
47. Thomsson AH, Biorch G, Bjorkman G, et al. Malignant carcinoid of the small intestine with metastasis to the liver, valvular disease of the right side of the heart, peripheral vascular symptoms, bronchoconstriction and an unusual type of cyanosis: a clinical and pathologic syndrome. Am Heart J 1954;47:795-817.
48. Rosenberg JC. Carcinoid and other amine producing tumors. Prog Clin Cancer 1966;2:297-308.
49. Wilander E, Portela-Gomes G, Grimelius L, Lundqvist G, Skoog V. Enteroglucagon and substance P like immunoreactivity in argentaffin and argyrophil rectal carcinoids. Virchows Arch B Cell Pathol 1977;25: 117-24.
50. Kaplan EL, Jaffe BM, Perkin GW. A new provocation test for the diagnosis of carcinoid syndrome. Am J Surg 1972;123:173-9.
51. Ahlman H, Dahlstrom A, Gronstad K, Jaffe BM, Nilsson O, Oberg K. The pentagastrin test in the diagnosis of the carcinoid syndrome. J Cardiovasc Pharmacol 1985; 7(Suppl):586-8.
52. Oberg K, Norheim I, Theodorsson E, Ahlman H, Lundqvist G, Wide L. The effects of octreotride on basal and stimulated hormone levels in patients with carcinoid syndrome. J Clin Endocrinol Metab 1989;68:796-800.
53. Ahlman H, Dahlstrom A, Enerback L, et al. Two cases of gastric carcinoids; diagnostic and therapeutic aspects. World J Surg 1988;12:356-61.
54. Lonroth H, Hakanson R, Lundell L, Sundler F. Histamine containing cells in the human stomach. Gut 1990; 31:383-8.
55. Nobin A, Axelsson S, Falck B, et al. Selective mesenteric vein catheterization and plasma serotonin determination in patients with carcinoid tumors. World J Surg 1983;7:223-9.
56. Von der Ohe MR, Camilleri M, Kvols LK. A 5HT3 antagonist corrects the postprandial colonic hypertonic response in carcinoid diarrhea. Gastroenterology 1994;106:1184-9.
57. Lucas KJ, Feldman JM. Flushing in the carcinoid syndrome and plasma kallikrein. Cancer 1986;58:2290-3.
58. Gustafsen J, Boesby S, Nielsen F, Giese J. Bradykinin in carcinoid syndrome. Gut 1987;28:1417-9.
59. Conlon JM, Deacon CF, Richter G, Stockmann F, Creutzfeldt W. Circulating tachykinins (substance P, neurokinin A, neuropeptide K) and the carcinoid flush. Scand J Gastroenterol 1987;22:97-105.
60. Furchgott RF, Zawadski JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetycholine. Nature 1980;288:373-6.
61. Smith AG, Greaves MW. Blood prostaglandin activity associated with noradrenaline-provoked flush in the carcinoid syndrome. Br J Dermatol 1974;90:547-51.
62. Jaffe BM, Condon S. Prostaglandins E and F in endocrine diarrheagenic syndromes. Ann Surg 1976;184: 516-24.
63. Roberts LJ 2nd, Marney SR Jr, Oates JA. Blockade of the flush associated with metastatic gastric carcinoid by combined H1 and H2 receptor antagonists: evidence for an important role of H2 receptors in human vasculature. N Engl J Med 1979;300:236-8.
64. Modlin IM, Gilligan CJ, Lawton GP, Tang LH, West AB, Darr U. Gastric carcinoids. The Yale experience. Arch Surg 1995;130:250-6.
65. Gilligan CJ, Lawton GP, Tang LH, West AB, Modlin IM. Gastric carcinoid tumors: the biology and therapy of an enigmatic and controversial lesion. Am J Gastroenterol 1995;90:338-52.
66. Rindi G, Bordi C, Rappel S, La Rosa S. Gastric carcinoids and neuroendocrine carcinomas: pathogenesis, pathology and behaviour. World J Surg 1996;20: 168-72.
67. Solcia E, Rindi G, Fiocca R, et al. Distinct patterns of chronic gastritis associated with carcinoid and cancer and their role in tumorigenesis. Yale J Biol Med 1992; 65:793-804.
68. Tormey WP, Fitzgerald RJ. The clinical and laboratory correlates of an increased urinary 5-hydroxyindole acetic acid. Postgrad Med J 1995;71:542-5.
69. Stridsberg M, Hellman U, Wilander E, Lundquist G, Hellsing K, Oberg K. Fragments of chromogranin A are present in urine of patients with carcinoid tumors: development of a specific radioimmunoassay for chromogranin A and its fragments. J Endocrinol 1993;139: 329-37.
70. Wallace S, Agani JA, Charnsangavej C, et al. Carcinoid tumor: images procedures and interventional radiology. World J Surg 1996;20:147-56.
71. Makridis C, Oberg K, Juhlin C, et al. Surgical treatment of mid-gut carcinoid tumors. World J Surg 1990;14: 377-83.
72. Cockey BM, Fishman EK, Jones B, Siegelman SS. Computed tomography of abdominal carcinoid tumor. J Comput Assist Tomogr 1985;9:38-42.
73. Goldstein HM, Miller M. Angiographic evaluation of carcinoid tumors of the small intestine: the value of epinephrine. Radiology 1975;114:23-8.
74. Collatz-Christensen S, Stage JG, Henriksen FW. Angiography in the diagnosis of carcinoid sydrome. Scand J Gastroenterol 1979;1(Suppl 53):11-4.
75. Andersson T, Eriksson B, Hemmingson A, Lindgren PG, Oberg K. Angiography computed tomography, magnetic resonance imaging and ultrasonography in detection of liver metastases from endocrine gastrointestinal tumors. Acta Radiol 1987;28:535-9.
76. Rioux M, Langis P, Naud F. Sonographic appearance of primary small bowel carcinoid tumor. Abdom Imaging 1995;20:37-43.
77. Andersson T, Eriksson B, Lindgren PG, Wilander E, Oberg K. Percutaneous ultrasonography-guided cutting biopsy from liver metastases of endocrine gastrointestinal tumors. Ann Surg 1987;206:728-32.
78. Zarrilli L, Marzano LA, Porcelli A, D'Avanzo A, Misso C. The surgical management of carcinoid tumors. J Nucl Biol Med 1991;35:341-2.
79. Yoshida M, Tsukamoto Y, Niwa Y, et al. Endoscopic assessment of invasion of colorectal tumours with a new high frequency ultrasound probe. Gastrointest Endosc 1995;41:587-92.
80. Yoshikane H, Tsukamoto Y, Niwa Y, et al. Carcinoid tumors of the gastrointestinal tract: evaluation with endoscopic ultrasonography. Gastrointest Endosc 1993;39:375-83.
81. Kweekkeboom DJ, Krenning EP. Somatostatin receptor scintigraphy in patients with carcinoid tumors. World J Surg 1996;20:157-61.
82. Kisker O, Weinel RJ, Geks J, Zacara F, Joseph K, Rothmund M. Value of somatostatin receptor scinigraphy in patients with carcinoid tumors. World J Surg 1996;20:162-7.
83. Meunier B, Le Cloirec J, Dazord L, et al. Per operative localization of a carcinoid tumor of the breast using indium-111 pentreotide and a nuclear surgical probe. Eur J Nucl Med 1995;22:281-3.
84. Eising EG, Farahati J, Bier D, Knust EJ, Reiners C. Somatostatin scintigraphy in medullary thyroid carcinomas, GEP and carcinoid tumors. Nuklearmedizin 1995;34:1-7.
85. Modlin M, Cornelius E, Lawton GP. Use of an isotopic somatostatin probe to image gut endocrine tumors. Arch Surg 1995;130:367-73.
86. Ahlman H, Wangberg B, Tisell LE, Nilsson O, Fjalling M, Forssell-Aronsson E. Clinical efficacy of octreotide scintigraphy in patients with midgut carcinoid tumors and evaluation of intraoperative scintillation detection. Br J Surg 1994;81:1144-9.
87. Dorr U, Rath U, Sautter-Bihl ML, et al. Improved visualization of carcinoid liver metastases by indium 111 pentreotide scintigraphy following treatment with cold somatostatin analogue. Eur J Nucl Med 1993;20:431-3.
88. Dorr U, Wurm K, Horing E, Guzman G, Rath U, Bihl H. Diagnostic reliability of somatostatin receptor scintigraphy during continuous treatment with different somatostatin analogues. Horm Metab Res 1993; 27(Suppl):36-43.
89. Castellani MR, Di Bartolomeo M, Maffioli L, Zilembo N, Gasparini M, Buraggi GL. (131-I) Metaiodobenzylguanidine therapy in carcinoid tumors. J Nucl Biol Med 1991:35:349-51.
90. Hoefnagel CA, Den Hartog Jager FC, Taal GB, Abeling NG, Engelsman EE. The role of 131-I MIGB in the diagnosis and therapy of carcinoids. Eur J Nucl Med 1987;13:187-91.
91. Hoefnagel CA, Den Hartog Jager FC, Van Gennip AH, Marcuse HR, Taal BG. Diagnosis and treatment of a carcinoid tumor using 131-I metaiodobenzylguanidine. Clin Nucl Med 1986;11:150-2.
92. Guerra P, Colombo L, Maira G, et al. Therapeutic possibilities of 131-I MIBG in metastatic carcinoid tumors: preliminary report. Tumori 1990;76:484-7.
93. Watanabe N, Seto H, Ishiki M, et al. I-123 MIBG imaging of metastic carcinoid tumor from the rectum. Clin Nucl Med 1995;20:357-60.
94. Oberg K. The action of alpha interferon on human carcinoid tumors. Semin Cancer Biol 1992;3:35-41.
95. Norton JA. Surgical management of carcinoid tumors: role of debulking and surgery for patients with advanced disease. Digestion 1994;55(Suppl 3):98-103.
96. Loftus JP, van Heerden JA. Surgical management of gastrointestinal carcinoid tumors. Adv Surg 1995;28: 317-36.
97. Stinner B, Kisker O, Zielke A, Rothmund M. Surgical management for carcinoid tumor of small bowel, appendix, colon and rectum. World J Surg 1996;20: 183-8.
98. Deans GT, Spence RA. Neoplastic lesions of the appendix. Br J Surg 1995;82:299-306.
99. Gouzi JL, Laigneau P, Delalande JP, et al. Indication for right hemicolectomy in carcinoid tumors of the appendix: the French Association for Surgical Research. Surg Gynecol Obstet 1993;176:543-7.
100. Robiolio PA, Rigolin VH, Harrison JK, et al. Predictors of outcome in tricuspid valve replacement in carcinoid heart disease. Am J Cardiol 1995;75:485-8.
101. MacGillavray DC, Heaton RB, Rushin JM, Cruess DF. Distant metsatases from a carcinoid tumor of the appendix less than one centimeter in size. Surgery 1992; 111:466-71.
102. Akerstrom G, Makridis C, Johansson H. Abdominal surgery in patients with midgut carcinoid tumors. Acta Oncol 1991;30:547-53.
103. Soreide O, Berstad T, Bakka A, et al. Surgical treatment as a principle in patients with advanced abdominal carcinoid tumors. Surgery 1992;111:48-54.
104. Yao LL. Surgical treatment of carcinoid - a report of 60 cases. Chung Hua Chung Liu Tsa Chih 1992;14:216-8.
105. Ahlman H, Westberg G, Wangberg B, et al. Treatment of liver metastases of carcinoid tumours. World J Surg 1996;20:196-202.
106. Davis Z, Moertel CG, McIlrath DC. The malignant carcinoid syndrome. Surg Gynecol Obstet 1973;137: 637-4.
107. Thompson GB, Van Heerden JA, Martin JK Jr, et al. Carcinoid tumors of the gastrointestinal tract; presentation, management and prognosis. Surgery 1985;98: 1054-62.
108. Buchanan KD, Johnston CF, O'Hare MM, et al. Neuroendocrine tumors: an European view. Am J Med 1986;81(Suppl):14-20.
109. Foster JH, Berman MM. Solid liver tumors. Major Probl Surg 1977;22:1-342.
110. Funa K, Papanicolaou V, Juhlin C, et al. Expression of platelet derived growth factor B-type receptors on stromal tissue cells in human carcinoid tumors. Cancer Res 1990;50:748-53.
111. Arnold JC, O'Grady JG, Bird GL, Calne RY, Williams R. Liver transplantation for primary and secondary apudomas. Br J Surg 1989;76:248-9.
112. Makowka L, Tzakis AG, Mazzaferro V, et al. Transplantation of the liver for metastatic endocrine tumors of the intestine and pancreas. Surg Gynecol Obstet 1989; 168:107-11.
113. Frilling A, Rogiers X, Knofel WT, Broelsch CE. Liver transplantation for metastatic carcinoid tumors. Digestion 1994;55(Suppl 3):104-6.
114. Sivula A, Sipponen P. The effect of hepatic dearterialisation and re-dearterialisation on carcinoid liver metastases. Ann Chir Gynaecol 1976;65:168-75.
115. Idema AA, Tjiong HS, Oldhoff J. Improvements of hepatic dearterialisation: a case report. J Surg Oncol 1980;13:197-205.
116. Khoury GA, Devine J, Bolt DE. Complete liver dearterialisation and the carcinoid syndrome. Br J Surg 1979;66:253-6.
117. McDermott WV, Hersle TW. Metastatic carcinoid to the liver treated by hepatic dearterialisation. Ann Surg 1974;180:305-8.
118. Chuang VP, Wallace S. Hepatic artery embolisation in the treatment of hepatic neoplasms. Radiology 1981; 140:51-8.
119. Hockerstedt K, Nieminen J, Scheinin TM. Liver blood flow after liver hilus dearterialisation. Ann Chir Gynaecol 1978;67:224-8.
120. Cho KJ, Reuter SR, Schmidt R. Effects of experimental hepatic artery embolisation on hepatic function. AJR Am J Roentgenol 1976;127:563-7.
121. Koehler RE, Korobkin M, Lewis F. Arteriographic demonstration of collateral arterial supply to the liver after hepatic artery ligation. Radiology 1975;117:49-54.
122. Bengmark S, Rosengren K. Angiographic study of the collateral circulation to the liver after ligation of the hepatic artery in man. Am J Surg 1970;119:620-4.
123. Winkelbauer FW, Niederle B, Pietschmann F, et al. Hepatic artery embolectomy of hepatic metastases from carcinoid tumors:value of using a mixture of cranacrylate and ethiodized oil. AJR Am J Roentgenol 1995;165:323-7.
124. Maton PN, Camilleri M, Griffin G, Allison DJ, Hodgson HJ, Chadwick VS. Role of hepatic arterial embolisation in the carcinoid syndrome. BMJ 1983;287:932-5.
125. Mitty HA, Warner RR, Newman LH, Train J, Parnes IH. Control of carcinoid syndrome with hepatic artery embolization. Radiology 1985;155:623-6.
126. Moertel CG, Johnson CM, McKusick MA, et al. The management of patients with advanced carcinoid and islet cell carcinomas. Ann Intern Med 1994;120:302-9.
127. Allison DJ, Jordan H, Hennessy O. Therapeutic embolisation of the hepatic artery: a review of 75 procedures. Lancet 1985;1:595-9.
128. Stockmann F, Creutzfeldt W. Approach to hepatic involvement by endocrine tumors of the gastrointestinal tract. Semin Liver Dis 1988;8:254-62.
129. Sjoblom SM, Hockerstedt K, Jarvinen H. Hepatic dearterialisation of carcinoid syndrome. Acta Chir Scand 1987;153:523-9.
130. Chakravarthy A, Abrams RA. Radiation therapy in the management of patients with malignant carcinoid tumors. Cancer 1995;75:1386-90.
131. Moertel CG, Hanley JA. Combination chemotherapy trials in metastatic carcinoid tumors and the malignant carcinoid syndrome. Cancer Clin Trials 1979;2:327-34.
132. Chernicoff D, Bukowski RM, Groppe CW Jr, Hawlett JS. Combination chemotherapy for islet cell carcinoma and metastatic carcinoid tumours with 5- fluorouracil and streptozocin. Cancer Treat Rep 1979;63:795-6.
133. Kvols LK, Buck M. Chemotherapy of metastatic carcinoid and islet cell tumors: a review. Am J Med 1987; 82(Suppl.5B):77-83.
134. Kvols LK. Metastatic carcinoid tumors and the carcinoid syndrome: a selective review of chemotherapy and hormonal therapy. Am J Med 1986;81:49-55.
135. Colomer R, Cortes-Funes H. Apud cell cancers. In: Cvitkovic E, Droz JP, Armand JP, Khoury S, eds. Handbook of chemotherapy in clinical oncology. Jersey: Scientific Communication International, 1993:683-4.
136. Fan JT, Ortiz RG, Buettner H. Regression of choroidal metastases from a bronchial carcinoid tumor after chemotherapy with cisplatin and etopside. Am J Ophthalomol 1994;117:111-3.
137. Ritzel U, Leonhardt U, Stockmann F, Ramadori G. Treatment of metastasizing midgut carcinoids with dacarbazine. Am J Gastroenterol 1995;90:627-31.
138. Bukowski RM, Tangen CM, Peterson RF, et al. Phase II trial of dimethyltriazenoimidazole carboxamide in patients with metastatic carcinoid: a Southwest Oncology Group study. Cancer 1994;73:1505-8.
139. Yoshizumi Y, Sugiura Y, Morisaki Y, Shima S, Tanaka S. Mitomycin-c-sensitive carcinoid tumor of the gall bladder: report of a case. Gan To Kagaku Ryoho 1992; 19:893-6.
140. Oberg K, Funa K, Alm G. Effects of leukocyte interferon on clinical symptoms and hormone levels in patients with midgut carcinoid tumors and the carcinoid syndrome. N Engl J Med 1983;309:129-33.
141. Hanssen LE, Schrumpf E, Kolbenstiedt AN, Tausjo J, Dolva LO. Treatment of malignant metastatic midgut carcinoid tumors with recominant human alpha 2b interferon with or without prior hepatic artery embolisation. Scand J Gastroenterol 1989;24:787-95.
142. Oberg K. Chemotherapy and biotherapy in neuroendocrine tumours. Curr Opin Oncol 1993;5:110-120.
143. Oberg K, Norheim I, Lind E, et al. The treatment of malignant carcinoid tumors with human leucocyte interferon: long term results. Cancer Treat Rep 1986;70: 1297-304.
144. Oberg K, Alm G, Magnusson A, Lundqvist G, et al. Treatment of malignant carcinoid tumor with recombinant interferon alpha-2b: developement of neutralising interferon antibodies and possible loss of antitumor activity. J Natl Cancer Inst 1989;81:531-5.
145. Nobin A, Lindblom A, Mansson B, Sundbert M. Interferon treatment in patients with malignant carcinoids. Acta Oncol 1989;28:445-9.
146. Valimaki M, Jarvinen H, Salmela P, Sane T, Sjobolm SM, Pelkonen R. Is the treatment of metastatic carcinoid tumor with interferon therapy not as successful as suggested? Cancer 1991;67:547-9.
147. Ahren B, Engman K, Lindblom A. Treatment of malignant midgut carcinoid syndrome with a highly purified human leucocyte alpha-interferon. Anticancer Res 1992;12:129-33.
148. Ahren B, Engman K, Lindblom A. Tolerance to long term treatment of malignant midgut carcinoid with a high purified human leukocyte alpha-interferon. Anticancer Res 1992;12:881-4.
149. Janson ET, Kauppinen HL, Oberg K. Combined alpha and gamma interferon therapy for malignant midgut carcinoids; a phase II trial. Acta Oncol 1993;32:231-3.
150. Janson ET, Ronnblom L, Ahlstrom H, et al. Treatment with alpha interferon versus alpha interferon in combination with streptozocin and doxorubicin in patients with malignant catcinoid tumors: a randomized trial. Ann Oncol 1992;3:635-8.
151. Saltz L, Kemeny N, Schwartz G, Kelsen D. A phase II trial of alpha interferon and 5-fluorouracil in patients with advanced carcinoid and islet cell tumors. Cancer 1994;74:958-61.
152. Diaco DS, Hajarizadeh H, Mueller CR, Fletcher WS, Pommier RF, Woltering EA. Treatment of metastatic carcinoid using multimodality therapy of octreotide acetate, intra arterial chemotherapy and hepatic chemoembolization. Am J Surg 1995;169:523-8.
153. Brazeau P, Vale W, Burgus R, et al. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 1973;179: 77-9.
154. Cohen ML, Rosing E, Wiley KS, Slater IH. Somatostatin inhibits adrenergic and cholinergic neurotransmission in smooth muscle. Life Sci 1978;23:1659-64.
155. Krulich L, Dhariwal AP, McCann SM. Stimulating and inhibitory effects of purified hypothalanic extracts on growth hormone release from rat pituitary in vitro. Endocrinology 1968;83:783-90.
156. Gerich JE. Somatostatin and diabetes. Am J Med 1981; 70:619-26.
157. Hall R, Snow M, Scanlon M, Mora B, Gomez-Pan A. Pituitary effects of somatostatin. Metabolism 1978; 27(Suppl 1):1257-62.
158. Reichlin S, Somatostatin. N Engl J Med 1983;309: 1495-501.
159. Arnold R. Medical treatment of metastasizing carcinoid tumors. World J Surg 1996;20:203-7.
160. Ruebi JC, Laissue J, Waser B, Horisberger U, Schaer JC. Expression of somatostatin receptors in normal inflammed and neoplastic human gastrointestinal tissues. Ann N Y Acad Sci 1994;773:122-37.
161. Frolich JC, Bloomgarden ZT, Oates JA, McGuigan JE, Rabinowitz D. The carcinoid flush: provocation by pentagastrin and inhibition by somatostatin. N Engl J Med 1978;299:1055-7.
162. Kvols LK, Martin JK, Mash HM, Moertel CG. Rapid reversal of carcinoid crisis with a somatostatin analogue [letter]. N Engl J Med 1985;313:1229.
163. Ahlman H, Ahlund L, Dahlstrom A, et al. Use of a somatostatin analogue in association with surgery and hepatic arterial embolisation in the treatment of carcinoid syndrome. Br J Cancer 1987;56:840-2.
164. Warner RR, Mani S, Profeta J, Grunstein E. Octreotide treatment of carcinoid hypertensive crisis. Mt Sinai J Med 1994;61:349-55.
165. Wadamori K, Oka M, Shimizu R, et al. A case of multiple liver metastases from ileal carcinoid effectively treated with continous intra artertial infusion of somatostatin analogue. Gan To Kagaku Ryoho 1995; 22:1669-72.
166. Lefebvre S, De Paepe L, Abs R, Rahier J, Selvais P, Maiter D. Subcutaneous octreotide treatment of a growth hormone-releasing hormone-secreting bronchial carcinoid:superiority of continous versus intermittent administration to control hormonal secretion. Eur J Endocrinol 1995;133:320-4.
167. Janson ET, Oberg K. Long term management of the carcinoid syndrome: treatment with octreotide alone and in combination with alpha interferon. Acta Oncol 1993;32:225-9.
168. Luzzatto G, Pozza M, Cella G. Soulagement symptomatique du syndrome carcinoide par la ketanserine: une observation. Presse Med 1995;24:897-9.
169. Schworer H, Munke H, Stockmann F, Ramadori G. Treatment of diarrhea in carcinoid syndrome with ondansetron, tropisetron and clonidine. Am J Gastroenterol 1995;90:645-8.
170. Godwin JD. Carcinoid tumors: an analysis of 2837 cases. Cancer 1975;36:560-9.
171. McDermott EW, Guduric B, Brennan MF. Prognostic variables in patients with gastrointestinal carcinoid tumors. Br J Surg 1994;81:1007-9.
172. Aranha GV, Greenlee HB. Surgical management of carcinoid tumors of the gastrointestinal tract. Am J Surg 1980;46:429-35.
173. Syracuse DC, Perzin KH, Price JB, et al. Carcinoid tumors of the appendix: mesoappendiceal extension and nodal metastases. Ann Surg 1979;190:58-63.
174. Strodel WE, Talpos G, Eckhauser F, Thompson N. Surgical therapy for small bowel carcinoid tumors. Arch Surg 1983;118:391-7.
175. Hermanek P, Sobin LH, eds. TMN classification of malignant tumours. Berlin: Springer, 1987:405-6.
176. Naunheim KS, Zeitels J, Kaplan EL, et al. Rectal carcinoid tumors: treatment and prognosis. Surgery 1983; 94:670-6.
177. Moertel CG, Dockerty MB, Judd ES. Carcinoid tumours of the vermiform appendix. Cancer 1968;21:270-8.
178. Foreman RC. Carcinoid tumours: report of 38 cases. Ann Surg 1952;136:838-55.
179. Warren WH, Coyle EB. Carcinoid tumors of gastrointestinal tract. Am J Surg 1951;82:373-7.
180. Schneider C, Wittekind C, Kockerling F. An unusual incidence of carcinoid tumors and secondary malignancies. Chirug 1995;66:607-11.
181. Ballantyne GH, Savoca PE, Flannery JT, Ahlman MH, Modlin IM. Incidence and mortality of carcinoids of the colon: data from the Connecticut Tumour Registry. Cancer 1992;69:2400-5.
182. Moyana TN, Xiang J. Expression of tumor associated polymorphic epithelial mucin and carcinoembryonic antigen in gastrointestinal carcinoid tumors: implications for immunodiagnosis and immunotherapy. Cancer 1995;75:2836-43.